Damien Dombrowski is an experienced patent litigator who has handled numerous jury and bench trials on behalf of plaintiffs and defendants, including a $107+ million patent infringement jury win. Damien also has significant experience with due diligence, complex multiparty settlement and license agreements, license/contract disputes, and opinion work. His experience includes technologies related to pharmaceuticals and formulations for the treatment of cancer, systemic fungal infections, psoriasis, lysosomal storage disorders, and respiratory conditions; cancer immunotherapy vaccines; eye vitamin supplements for macular degeneration; DNA sequencing technology; and hardware and software for image sensors and touchscreens/displays.
After a five-day jury trial and over four years of litigation on behalf of client Vectura against defendant GlaxoSmithKline (GSK), Damien's team obtained an $89.7 million verdict of infringement, willful infringement, and non-obviousness of a Vectura patent on inhalation formulation technology, which the District Court increased to $107 million, and the jury further awarded an ongoing royalty on U.S. sales of GSK's infringing Breo Ellipta, Anoro Ellipta, and Incruse Ellipta inhaler products. The Federal Circuit affirmed. Among many other contributions to the litigation, Damien cross-examined GSK's main infringement and invalidity expert at trial and was the lead brief writer throughout the case and on appeal.